Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05663489
Other study ID # BCBP-1
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 23, 2018
Est. completion date December 11, 2027

Study information

Verified date December 2022
Source Haukeland University Hospital
Contact Bjarne Hansen, PhD
Phone +4792090765
Email bjarne.kristian.aaslie.hansen@helse-bergen.no
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Obsessive-compulsive disorder (OCD) and anxiety disorders are common and debilitating conditions which are often chronic when treatment is not provided. International guidelines recommend cognitive behavioral therapy (CBT) as the first-line treatment, and research has shown that CBT can be delivered over a concentrated period of time. The Bergen 4-Day Treatment (B4DT) is an exposure-based treatment which is delivered over four consecutive days. B4DT has been shown to induce rapid and long-lasting remission in around 70% of patients. This provides a platform for studying psychological and neurobiological changes associated with treatment response and non-response. The present study will investigate longitudinal changes in psychological measures and DNA methylation in patients who receive the B4DT, as well as a subset will also undergo multimodal brain imaging.


Description:

The primary study will include 500 OCD patients who will receive the B4DT. Symptom severity will be prospectively measured before treatment, approximately 10 days after treatment and three months after treatment. Saliva samples will be collected for later extraction of DNA methylation during the first day of treatment, the last day of treatment, and three months after treatment. A substudy will use multimodal magnetic resonance imaging (MRI) before treatment, approximately 10 days after treatment and three months after treatment. The substudy will also 100 patients with social anxiety disorder or panic disorder for DNA methylation and MRI, as well as 50 healthy controls for MRI. Clinical data will be collected from a consent-based quality register ("Kvalitetsregister for konsentrerte behandlingsformat"). The aim of the study is to investigate changes in DNA methylation as well as functional and structural brain networks that occur in patients undergoing B4DT, and to correlate these changes with immediate and long-term response to treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date December 11, 2027
Est. primary completion date August 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: - Diagnosed with obsessive-compulsive disorder, panic disorder or social anxiety disorder using DSM-5 criteria - Referred to National Clinic for 4-Day Treatment, Haukeland University Hospital, Bergen, Norway - Consented to participate in the "Kvalitetsregister for konsentrerte behandlingsformat" Exclusion Criteria: - Suicidal, ongoing mania, primary eating disorder, intellectual disability, ongoing psychosis, ongoing substance abuse For MRI substudy: Inclusion Criteria: - For the healthy controls, no previous or current psychiatric disorders as detected by the Mini International Neuropsychiatric Interview (MINI) Exclusion Criteria: - MRI incompatibility (e.g. pregnancy, metal implants)

Study Design


Intervention

Behavioral:
Bergen 4-Day Treatment (B4DT)
A concentrated and exposure-based psychological treatment over four consecutive days

Locations

Country Name City State
Norway Bergen Center for Brain Plasticity Bergen Vestland

Sponsors (7)

Lead Sponsor Collaborator
Haukeland University Hospital Amsterdam UMC, location VUmc, Harvard Medical School (HMS and HSDM), Oslo University Hospital, University of Bergen, University of North Carolina, Chapel Hill, University of Oslo

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Symptom severity of obsessive-compulsive disorder Before treatment
Primary Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Symptom severity of obsessive-compulsive disorder approximately 10 days after treatment
Primary Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Symptom severity of obsessive-compulsive disorder three months after treatment
Primary Panic Disorder Severity Scale (PDSS) Symptom severity of panic disorder Before treatment
Primary Panic Disorder Severity Scale (PDSS) Symptom severity of panic disorder approximately 10 days after treatment
Primary Panic Disorder Severity Scale (PDSS) Symptom severity of panic disorder three months after treatment
Primary Liebowitz Social Anxiety Scale (LSAS) Symptom severity of social anxiety disorder Before treatment
Primary Liebowitz Social Anxiety Scale (LSAS) Symptom severity of social anxiety disorder approximately 10 days after treatment
Primary Liebowitz Social Anxiety Scale (LSAS) Symptom severity of social anxiety disorder three months after treatment
Secondary DNA Methylation Samples of saliva will be collected for genome-wide methylation and profiling will be carried out using the Illumina Infinium MethylationEPIC BeadChip system Before treatment
Secondary DNA Methylation Samples of saliva will be collected for genome-wide methylation and profiling will be carried out using the Illumina Infinium MethylationEPIC BeadChip system approximately 10 days after treatment
Secondary DNA Methylation Samples of saliva will be collected for genome-wide methylation and profiling will be carried out using the Illumina Infinium MethylationEPIC BeadChip system three months after treatment
Secondary Magnetic Resonance Imaging Brain functional and structural MRI will be collected for a subset of 100 OCD and 100 anxiety disorder patients as well as 50 healthy controls Before treatment
Secondary Magnetic Resonance Imaging Brain functional and structural MRI will be collected for a subset of 100 OCD and 100 anxiety disorder patients as well as 50 healthy controls approximately 10 days after treatment
Secondary Magnetic Resonance Imaging Brain functional and structural MRI will be collected for a subset of 100 OCD and 100 anxiety disorder patients as well as 50 healthy controls three months after treatment
See also
  Status Clinical Trial Phase
Recruiting NCT04934007 - Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder N/A
Recruiting NCT04071990 - Family Involvement in CBGT of OCD: a Randomized Controlled Trial N/A
Completed NCT02541968 - Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Recruiting NCT05391503 - Light Therapy for Obsessive-compulsive Disorder (OCD) N/A
Recruiting NCT04539951 - Pragmatic Trial of Obsessive-compulsive Disorder Phase 2
Completed NCT03416504 - Methods for Managing Intrusive Thoughts N/A
Not yet recruiting NCT06029738 - Effect on Obsessive-Compulsive Beliefs and Symptoms of MCT-OCD N/A
Recruiting NCT02844049 - European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS N/A
Terminated NCT02909660 - What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder N/A
Completed NCT02911324 - Cannabinoid Medication for Adults With OCD Phase 1/Phase 2
Completed NCT02217995 - Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients N/A
Terminated NCT02234011 - A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder Phase 2
Withdrawn NCT01953042 - Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders N/A
Completed NCT02655926 - Deep Brain Stimulation for Severe Obsessive Compulsive Disorder N/A
Completed NCT00742664 - Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project Phase 1/Phase 2
Terminated NCT00758966 - Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder Phase 2
Completed NCT04919785 - Deep Brain Stimulation in Severe Obsessive-compulsive Disorder N/A
Completed NCT00523718 - Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder Phase 2
Completed NCT00074815 - Treatment of Obsessive Compulsive Disorder in Children Phase 3